Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport in Upper Back Myofascial Pain Syndrome
NCT00134810Phase 2Completed
- Sponsor
- Ipsen
- Start
- Mar 2005
- Primary completion
- May 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of abobotulinumtoxinA in myofascial pain syndrome (MPS) (4 arms), sponsored by Ipsen. Primary endpoint: Change in pain score for 'overall pain of the day during activity' at 6 weeks. Started Mar 2005; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
myofascial pain syndrome (MPS)
Beyond the preview
Go deeper on NCT00134810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134810.